Back to discover

Protein / target

Fatty acid-binding protein, brain

Encoded byFABP7O15540Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
3
Research papers

Protein at a glance

Biological role

Lipid transporter

Strongest disease association

Idiopathic Pulmonary Fibrosis

Via encoding gene FABP7 · Genetic evidence · score 0.41

Research activity

Emerging research

3 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development.

View complete UniProt function annotation

B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development. It is required for the establishment of the radial glial fiber system in developing brain, a system that is necessary for the migration of immature neurons to establish cortical layers (By similarity)

Subcellular location

Cytoplasm
Domains and Gene Ontology detail (10)

Gene Ontology

  • Ccytosol
  • Cnucleus
  • Ffatty acid binding
  • Flipid binding
  • Flipid transporter activity
  • Pepithelial cell proliferation
  • Pfatty acid transport
  • Pnegative regulation of cell population proliferation
  • Pnervous system development
  • Ptriglyceride catabolic process

132 aa · 15 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismGOCell proliferation & survivalGO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·fatty acid binding
  • ·lipid transporter activity
  • ·fatty acid transport
  • ·triglyceride catabolic process

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FABP7

Gene-level evidence surfaced through the gene FABP7that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Idiopathic Pulmonary Fibrosis
0.41Limited support

Genetic evidence dominant · Open Targets 0.25

Alcohol drinking
0.25Preliminary

Genetic evidence dominant · Open Targets 0.15

Urolithiasis
0.22Preliminary

Genetic evidence dominant · Open Targets 0.13

Temporomandibular Joint Disorders
0.21Preliminary

Genetic evidence dominant · Open Targets 0.13

Breast Neoplasms
0.18Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

View evidence synthesis (5)
Idiopathic Pulmonary FibrosisLimited support
0.41
agreement 0.290.53
Genetic100%

Open Targets aggregate 0.25 · 1 independent evidence family

Alcohol drinkingPreliminary
0.25
agreement 0.130.37
Genetic100%

Open Targets aggregate 0.15 · 1 independent evidence family

UrolithiasisPreliminary
0.22
agreement 0.100.34
Genetic100%

Open Targets aggregate 0.13 · 1 independent evidence family

Temporomandibular Joint DisordersPreliminary
0.21
agreement 0.090.33
Genetic100%

Open Targets aggregate 0.13 · 1 independent evidence family

Breast NeoplasmsPreliminary
0.18
agreement 0.000.37
Literature72%RNA expression28%

Open Targets aggregate 0.11 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Idiopathic Pulmonary Fibrosis0.25
Alcohol drinking0.15
Urolithiasis0.13
Temporomandibular Joint Disorders0.13
Breast Neoplasms0.11
Glioblastoma0.11
Neoplasms0.11
Glioma0.10

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (half-life data and small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

3 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.